Traduction de «person-to-person spread disease » (Anglais → Français) :

Question No. 53 Ms. Kirsty Duncan: With respect to the chronic cerebrospinal venous insufficiency (CCSVI) clinical trial being undertaken by Dr. Traboulse: (a) what milestones are reportable to the government, (i) on what date(s) is reporting expected to occur, (ii) how will this information be communicated to patients, the medical community, and the general public; (b) on what date did each of the trial sites pass ethical review; (c) on what date did recruitment of patients begin for each of the trial sites; (d) how many patients with multiple sclerosis (MS) are being recruited for each site, and how is consistency in diagnosis and treatment being ensured across sites; (e) who is performing the diagnoses for CCSVI for each site, (i) ho ...[+++]w is the diagnosis being performed, including, but not limited to, ultrasound and venogram, (ii) how many diagnoses has each person undertaking the diagnosis at each site performed prior to the study, and by whom was each person trained; (f) who is performing the procedures for each site, (i) how is the procedure being performed, including, but not limited to, anesthetic, balloon size, (ii) how many procedures has each person undertaking the procedure at each site performed prior to the study, and by whom was each person trained; (g) what are the selection criteria for the trial, including, but not limited to, type of MS, Expanded Disability Status Scale (EDSS) score, venous abnormality/malformed valve/stenosis, mobility, (i) how do these criteria compare with the international literature, (ii) with how many international studies to date will the selection criteria be analytically comparable; (h) if both progressive and relapsing-remitting forms of MS are to be examined in the trial, how will statistical significance be ensured given that 50 of 100 patients will undergo a “sham” procedure, 25 patients will have a progressive form of the disease, and 25 will have a relapsing-remitting form of the disease, and will people with bo ...

This includes information about the natural person collected in the course of the registration for, or the provision of, health care services as referred to in Directive 2011/24/EU of the European Parliament and of the Council to that natural person; a number, symbol or particular assigned to a natural person to uniquely identify the natural person for health purposes; information derived from the testing or examination of a body part or bodily substance, including from genetic data and biological samples; and any information on, for example, a disease, disability, disease risk, medical history, clinical treatment or the physiological ...[+++] or biomedical state of the data subject independent of its source, for example from a physician or other health professional, a hospital, a medical device or an in vitro diagnostic test.

34(1) Before arriving in Canada, the operator of a conveyance used in a business of carrying persons or cargo, or of any prescribed conveyance, shall report to the authority designated under paragraph 63(b) situated at the nearest entry point any reasonable grounds to suspect that (a) any person, cargo or other thing on board the conveyance could cause the spreading of a communicable disease listed in the schedule; (b) a person on board the conveyance has died; or (c) any prescribed circumstances exist.

In particular when communicating personal data within the EWRS with a view to prevent and stop the spread of communicable diseases, the competent public health authorities of Member States and the Commission should ensure that personal data is adequate, relevant and not excessive in relation to that purpose as well as not processed for other purposes, and that it is accurate, updated when necessary and kept for no longer than necessary for that purpose; they should also ensure that persons subject to contact tracing are duly informed of the nature of the processing, of the data processed, of the rights to access and rectify data concern ...[+++]ing them, unless this proves impossible or involves a disproportionate effort, and that appropriate levels of confidentiality and security are put in place within the EWRS to protect the processing of such data.

on reasonable grounds that the traveller has a communicable disease or is infested with vectors, or has recently been in close proximity with a person who has acommunicable disease or is infested with vectors, the quarantine officer may order the traveller to comply with treatment or any other measure for preventing or controlling the spread of a communicable disease.

Consequently, a person with Alzheimer’s disease has less brain tissue than a person who does not have the illness; the shrinkage continues over time, affecting how the brain functions.[201] Memory loss is the most prominent early symptom of Alzheimer’s disease, often followed by a slow deterioration of cognitive functions and personality features and physical capacity.